SciGen partner increases investment
Friday, 04 November, 2005
The two largest shareholders in Singapore-based, ASX-listed biopharmaceutical company SciGen (ASX:SIE), SciTech Medical and Bioton, have entered into a share exchange agreement which may result in Bioton gaining a 44.7 per cent equity share in SciGen.
Under the agreement between Polish company Bioton and Singapore private healthcare company SciTech, Bioton will invest AUD$30 million to accelerate the launch of SciGen's portfolio of biopharmaceutical products to market.
SciTech is selling its shares to Bioton for $0.075 per SciGen share, a premium to the ASX market price of $0.067 at close of trading on Friday 28 October when the deal was entered into.
Saul Mashaal will remain as SciGen's executive vice-chairman and CEO, and will be elected to the supervisory board of Bioton.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
